Global Parkinson Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

According to APO Research, The global Parkinson Disease Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Parkinson Disease Drug include Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma and Astellas Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Parkinson Disease Drug, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Parkinson Disease Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Parkinson Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Parkinson Disease Drug revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Parkinson Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Parkinson Disease Drug revenue, projected growth trends, production technology, application and end-user industry.


Parkinson Disease Drug Segment by Company

Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health

Parkinson Disease Drug Segment by Type

Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other

Parkinson Disease Drug Segment by Application

Under 40 Years Old
40-65 Years Old
Above 65 Years Old

Parkinson Disease Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Parkinson Disease Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parkinson Disease Drug industry.
Chapter 3: Detailed analysis of Parkinson Disease Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinson Disease Drugrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Parkinson Disease Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Sinemet-CR
1.2.3 Trastal
1.2.4 Madopar
1.2.5 COMT Inhibitor
1.2.6 Other
1.3 Market Analysis by Application
1.3.1 Global Parkinson Disease Drug Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Global Market Growth Prospects
1.5 Global Parkinson Disease Drug Growth Trends by Region
1.5.1 Global Parkinson Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Parkinson Disease Drug Market Size by Region (2020-2025)
1.5.3 Parkinson Disease Drug Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Parkinson Disease Drug Market Dynamics
2.1 Parkinson Disease Drug Industry Trends
2.2 Parkinson Disease Drug Industry Drivers
2.3 Parkinson Disease Drug Industry Opportunities and Challenges
2.4 Parkinson Disease Drug Industry Restraints
3 Competitive Landscape by Company
3.1 Global Parkinson Disease Drug Revenue by Company (2020-2025)
3.2 Global Parkinson Disease Drug Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Parkinson Disease Drug Key Company Head office and Area Served
3.4 Global Parkinson Disease Drug Company, Product Type & Application
3.5 Global Parkinson Disease Drug Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Parkinson Disease Drug Market CR5 and HHI
3.6.2 Global Top 5 and 10 Parkinson Disease Drug Players Market Share by Revenue in 2024
3.6.3 2024 Parkinson Disease Drug Tier 1, Tier 2, and Tier 3
4 Parkinson Disease Drug Market by Type
4.1 Global Parkinson Disease Drug Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Parkinson Disease Drug Market Size by Type (2020-2031)
4.3 Global Parkinson Disease Drug Market Size Share by Type (2020-2031)
5 Parkinson Disease Drug Market by Application
5.1 Global Parkinson Disease Drug Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Parkinson Disease Drug Market Size by Application (2020-2031)
5.3 Global Parkinson Disease Drug Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Merck
6.1.1 Merck Comapny Information
6.1.2 Merck Business Overview
6.1.3 Merck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Merck Parkinson Disease Drug Product Portfolio
6.1.5 Merck Recent Developments
6.2 Akorn
6.2.1 Akorn Comapny Information
6.2.2 Akorn Business Overview
6.2.3 Akorn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Akorn Parkinson Disease Drug Product Portfolio
6.2.5 Akorn Recent Developments
6.3 GSK
6.3.1 GSK Comapny Information
6.3.2 GSK Business Overview
6.3.3 GSK Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 GSK Parkinson Disease Drug Product Portfolio
6.3.5 GSK Recent Developments
6.4 Novartis
6.4.1 Novartis Comapny Information
6.4.2 Novartis Business Overview
6.4.3 Novartis Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 Novartis Parkinson Disease Drug Product Portfolio
6.4.5 Novartis Recent Developments
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Comapny Information
6.5.2 Boehringer Ingelheim Business Overview
6.5.3 Boehringer Ingelheim Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments
6.6 Teva Pharmaceutical
6.6.1 Teva Pharmaceutical Comapny Information
6.6.2 Teva Pharmaceutical Business Overview
6.6.3 Teva Pharmaceutical Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
6.6.5 Teva Pharmaceutical Recent Developments
6.7 Abbvie
6.7.1 Abbvie Comapny Information
6.7.2 Abbvie Business Overview
6.7.3 Abbvie Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Abbvie Parkinson Disease Drug Product Portfolio
6.7.5 Abbvie Recent Developments
6.8 Kyowa Hakko Kirin Pharma
6.8.1 Kyowa Hakko Kirin Pharma Comapny Information
6.8.2 Kyowa Hakko Kirin Pharma Business Overview
6.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
6.8.5 Kyowa Hakko Kirin Pharma Recent Developments
6.9 Astellas Pharma
6.9.1 Astellas Pharma Comapny Information
6.9.2 Astellas Pharma Business Overview
6.9.3 Astellas Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
6.9.5 Astellas Pharma Recent Developments
6.10 Desitin Arzneimittel
6.10.1 Desitin Arzneimittel Comapny Information
6.10.2 Desitin Arzneimittel Business Overview
6.10.3 Desitin Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
6.10.5 Desitin Arzneimittel Recent Developments
6.11 Endo Pharmaceuticals
6.11.1 Endo Pharmaceuticals Comapny Information
6.11.2 Endo Pharmaceuticals Business Overview
6.11.3 Endo Pharmaceuticals Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
6.11.5 Endo Pharmaceuticals Recent Developments
6.12 F.Hoffmann-La Roche
6.12.1 F.Hoffmann-La Roche Comapny Information
6.12.2 F.Hoffmann-La Roche Business Overview
6.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
6.12.5 F.Hoffmann-La Roche Recent Developments
6.13 H.Lundbeck
6.13.1 H.Lundbeck Comapny Information
6.13.2 H.Lundbeck Business Overview
6.13.3 H.Lundbeck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
6.13.5 H.Lundbeck Recent Developments
6.14 Valeant
6.14.1 Valeant Comapny Information
6.14.2 Valeant Business Overview
6.14.3 Valeant Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.14.4 Valeant Parkinson Disease Drug Product Portfolio
6.14.5 Valeant Recent Developments
6.15 Apokyn
6.15.1 Apokyn Comapny Information
6.15.2 Apokyn Business Overview
6.15.3 Apokyn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.15.4 Apokyn Parkinson Disease Drug Product Portfolio
6.15.5 Apokyn Recent Developments
6.16 Orion
6.16.1 Orion Comapny Information
6.16.2 Orion Business Overview
6.16.3 Orion Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.16.4 Orion Parkinson Disease Drug Product Portfolio
6.16.5 Orion Recent Developments
6.17 Stada Arzneimittel
6.17.1 Stada Arzneimittel Comapny Information
6.17.2 Stada Arzneimittel Business Overview
6.17.3 Stada Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
6.17.5 Stada Arzneimittel Recent Developments
6.18 US WorldMeds
6.18.1 US WorldMeds Comapny Information
6.18.2 US WorldMeds Business Overview
6.18.3 US WorldMeds Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
6.18.5 US WorldMeds Recent Developments
6.19 Bausch Health
6.19.1 Bausch Health Comapny Information
6.19.2 Bausch Health Business Overview
6.19.3 Bausch Health Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
6.19.5 Bausch Health Recent Developments
7 North America
7.1 North America Parkinson Disease Drug Market Size (2020-2031)
7.2 North America Parkinson Disease Drug Market Size by Type
7.2.1 North America Parkinson Disease Drug Market Size by Type (2020-2025)
7.2.2 North America Parkinson Disease Drug Market Size by Type (2026-2031)
7.2.3 North America Parkinson Disease Drug Market Share by Type (2020-2031)
7.3 North America Parkinson Disease Drug Market Size by Application
7.3.1 North America Parkinson Disease Drug Market Size by Application (2020-2025)
7.3.2 North America Parkinson Disease Drug Market Size by Application (2026-2031)
7.3.3 North America Parkinson Disease Drug Market Share by Application (2020-2031)
7.4 North America Parkinson Disease Drug Market Size by Country
7.4.1 North America Parkinson Disease Drug Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Parkinson Disease Drug Market Size by Country (2020-2025)
7.4.3 North America Parkinson Disease Drug Market Size by Country (2026-2031)
7.4.4 North America Parkinson Disease Drug Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Parkinson Disease Drug Market Size (2020-2031)
8.2 Europe Parkinson Disease Drug Market Size by Type
8.2.1 Europe Parkinson Disease Drug Market Size by Type (2020-2025)
8.2.2 Europe Parkinson Disease Drug Market Size by Type (2026-2031)
8.2.3 Europe Parkinson Disease Drug Market Share by Type (2020-2031)
8.3 Europe Parkinson Disease Drug Market Size by Application
8.3.1 Europe Parkinson Disease Drug Market Size by Application (2020-2025)
8.3.2 Europe Parkinson Disease Drug Market Size by Application (2026-2031)
8.3.3 Europe Parkinson Disease Drug Market Share by Application (2020-2031)
8.4 Europe Parkinson Disease Drug Market Size by Country
8.4.1 Europe Parkinson Disease Drug Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Parkinson Disease Drug Market Size by Country (2020-2025)
8.4.3 Europe Parkinson Disease Drug Market Size by Country (2026-2031)
8.4.4 Europe Parkinson Disease Drug Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Parkinson Disease Drug Market Size (2020-2031)
9.2 China Parkinson Disease Drug Market Size by Type
9.2.1 China Parkinson Disease Drug Market Size by Type (2020-2025)
9.2.2 China Parkinson Disease Drug Market Size by Type (2026-2031)
9.2.3 China Parkinson Disease Drug Market Share by Type (2020-2031)
9.3 China Parkinson Disease Drug Market Size by Application
9.3.1 China Parkinson Disease Drug Market Size by Application (2020-2025)
9.3.2 China Parkinson Disease Drug Market Size by Application (2026-2031)
9.3.3 China Parkinson Disease Drug Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Parkinson Disease Drug Market Size (2020-2031)
10.2 Asia Parkinson Disease Drug Market Size by Type
10.2.1 Asia Parkinson Disease Drug Market Size by Type (2020-2025)
10.2.2 Asia Parkinson Disease Drug Market Size by Type (2026-2031)
10.2.3 Asia Parkinson Disease Drug Market Share by Type (2020-2031)
10.3 Asia Parkinson Disease Drug Market Size by Application
10.3.1 Asia Parkinson Disease Drug Market Size by Application (2020-2025)
10.3.2 Asia Parkinson Disease Drug Market Size by Application (2026-2031)
10.3.3 Asia Parkinson Disease Drug Market Share by Application (2020-2031)
10.4 Asia Parkinson Disease Drug Market Size by Country
10.4.1 Asia Parkinson Disease Drug Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Parkinson Disease Drug Market Size by Country (2020-2025)
10.4.3 Asia Parkinson Disease Drug Market Size by Country (2026-2031)
10.4.4 Asia Parkinson Disease Drug Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Parkinson Disease Drug Market Size (2020-2031)
11.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Type
11.2.1 South America, Middle East & Africa Parkinson Disease Drug Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Parkinson Disease Drug Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Parkinson Disease Drug Market Size by Application
11.3.1 South America, Middle East & Africa Parkinson Disease Drug Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Parkinson Disease Drug Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country
11.4.1 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Parkinson Disease Drug Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings